CMS’s RAPID Coverage Pathway for Breakthrough Devices: What the August 2026 Procedural Notice Actually Does, Why TCET Got Paused, and Why the First Same-Day NCD Probably Lands After 2030
Video Preview
🎧 Part I Podcast free on Spotify.
🎧 Part II Podcast episode for paid subscribers only. Also available on Spotify.
To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
Table of Contents
Three brands, one unsolved problem
What the notice actually says
The eligibility gate is narrower than the press release
The IVD carve-out, or how MolDX kept its kingdom
Coverage is not payment, and payment is where the year goes
The same-day NCD is hostage to FDA’s publishing calendar
CED is where the Class III devices go to sit down
Trial economics: what it costs to design for two agencies
The free option, and the adverse selection it invites
Medicare Advantage, commercial followers, and the real prize
Timeline math: when the first RAPID NCD actually shows up
What belongs in a comment letter before the window closes
Where this leaves builders and capital
Abstract
CMS published CMS-3487-NC on August 11, 2026, a notice with comment period establishing the Regulatory Alignment for Predictable and Immediate Device coverage pathway. Comments close 60 days out, roughly October 10.
The core promise: a proposed NCD posted the same day as FDA market authorization, 30-day comment period, final NCD around 60 days post-authorization for Class II and 90 days for Class III. Compare to the 9 to 12 months the NCD process normally eats.
Eligibility is tight: presumptive Class II Breakthrough devices in FDA’s TAP heading for a De Novo, or Class III Breakthrough devices heading for a PMA, and only at the IDE pre-submission stage. In vitro diagnostics are excluded outright.
TCET is paused for new candidates as of publication. Parallel Review survives. RAPID NCDs jump the NCD wait list.
The structural catch: pre-submission-only entry means the first device to actually complete the pathway is a late-decade event, unless CMS adopts the temporary on-ramp it explicitly asks about.
The other structural catch: an NCD is a coverage decision, not a payment rate. Coding and rate-setting cycles still run on their own clocks.
Three brands, one unsolved problem
The gap between FDA market authorization and Medicare coverage has been the medtech industry’s favorite complaint for about fifteen years, and it has now generated three separate federal attempts to fix it, each with a different acronym and each announced with the confidence of someone who has not read the previous two. MCIT arrived in January 2021, would have handed every Breakthrough-designated device four years of automatic national coverage, and was repealed that November on the grounds that automatic coverage for devices never tested in older patients with four comorbidities is a strange way to run an insurance program. TCET landed in August 2024, promised a final NCD within six months of market authorization, and then capped itself at about five candidates a year, which for an FDA program that has issued north of a thousand Breakthrough designations since 2015 is less a pathway than a lottery. RAPID showed up on April 23, 2026 as a joint CMS and FDA announcement and became a real document on August 11, 2026.
So the problem is genuinely hard, and the industry’s framing of it has always been slightly self-serving. The framing goes: FDA cleared it, therefore Medicare should pay for it. CMS has been consistent for two decades that these are different questions under different statutes. FDA asks whether a device is safe and effective for its labeled indication. CMS asks whether the thing is reasonable and necessary for the diagnosis or treatment of illness or injury in a population that skews 65-plus, where roughly half of patients carry two or more chronic diseases, and where the pivotal trial that got the device authorized may have excluded exactly those people because comorbidity muddies an effect size. That is not bureaucratic obstinance. That is two agencies with two statutes and one shared inability to make the other one’s problem go away.
What makes RAPID interesting is that it does not try to resolve the tension by fiat, the way MCIT did. It resolves it by moving the conversation about four years earlier, to the moment when a manufacturer is still sketching an IDE protocol and has not yet spent the money. That is the right instinct. Whether the execution survives contact with coding cycles, benefit categories, and the calendar is the rest of this essay.
What the notice actually says
Strip the preamble and the pathway is three stages. Stage one is IDE pre-submission. A manufacturer that already has Breakthrough designation, and TAP enrollment where applicable, emails FDA’s TAP program before filing an IDE pre-sub and says it wants in. FDA screens for initial eligibility, loops in CMS, and CMS runs a preliminary benefit category assessment. Then there is a kickoff meeting with all three parties where the manufacturer walks its clinical study synopsis and CMS and FDA give live reactions. The manufacturer then requests formal written feedback, which comes back as combined FDA and CMS comments on whether the proposed endpoints will actually support an NCD, whether the CMS IDE criteria are satisfied, and where the evidence gaps sit.
Stage two is the formal IDE submission. FDA reviews on its normal clock and issues a decision letter that includes study design considerations. FDA shares that letter, considerations included, with CMS. CMS then talks directly to the manufacturer about which considerations must be addressed to stay in the pathway, and once those are resolved and FDA has blessed any revised protocol, the manufacturer submits the protocol to CMS through the existing centralized IDE review process that has been running since 2015 under 42 CFR 405.212. If everything checks out, CMS issues an approval letter that includes a stated intent to issue a proposed NCD concurrently with market authorization. Any subsequent protocol change needs both agencies to sign off or the device falls out.
Stage three is the transition to coverage. FDA shares the IDE final report with CMS. When the marketing submission is accepted for review, CMS gets the clinical study report. The manufacturer sends a formal NCD request cover letter. On the day FDA grants market authorization, CMS posts a tracking sheet and a proposed NCD, opens a 30-day comment period, and targets a final NCD at roughly 60 days post-authorization for Class II and 90 for Class III. Coverage is limited to the FDA-authorized indications. If the evidence has gaps, the NCD comes out under coverage with evidence development instead of straight 1862(a)(1)(A) coverage.
Worth noting that none of this requires new statutory authority, which is why it is a procedural notice and not a rule. The 60 and 90 day targets fit inside the existing NCD statutory clock, which allows 60 days after the close of the comment period to issue a final decision. RAPID is not bending the law. It is doing the analytical work in advance so the clock starts from a running start instead of a cold one. The flip side of not needing rulemaking is that the whole thing can be undone by a future notice on a Tuesday afternoon, with no rulemaking record, no appeal rights, and nothing for a manufacturer to sue over if CMS decides in year three that the pathway is inconvenient.
The eligibility gate is narrower than the press release
Read the criteria closely and the addressable population shrinks fast. Class II devices qualify only if they hold Breakthrough designation, are enrolled in FDA’s TAP program, and plan to submit a De Novo request. Class III devices qualify if they hold Breakthrough designation and plan to submit a PMA, TAP participation optional. There is a footnote that lets in 510(k)-cleared devices where the primary predicate was authorized via De Novo no earlier than 18 months before acceptance, which is a narrow window designed to catch second-movers in a brand new device category and not much else. Everything else is out.
Then comes the timing gate, which is the one that matters most. The device must be at the IDE pre-submission stage. Not market-authorized. Not mid-study. Pre-submission. If the IDE study is already enrolling, the door is closed, and CMS says plainly that such devices belong in a conventional NCD request, an LCD, or claim-by-claim adjudication. CMS knows this is the binding constraint, because it explicitly solicits comment on whether to build a temporary process letting devices already under an active IDE become eligible, subject to an assessment of whether the running study evaluates the right outcomes or could be amended to do so. That request for comment is the single most consequential paragraph in the document for anyone with a device in the clinic today.
The quieter constraint is the phrase separately payable. The device has to be something that can be billed to Medicare on its own if approved. That knocks out an enormous share of implantables and procedural devices whose cost is packaged into a DRG or an APC and never appears as its own line. A transcatheter valve, a neurostimulator lead, a surgical mesh: these get paid through the procedure, not as separately payable items, absent a pass-through or new-technology add-on designation. So the pathway naturally biases toward durable medical equipment, devices with their own HCPCS identity, and technologies that will plausibly qualify for pass-through status. That is a real category, but it is not the whole Breakthrough pipeline, and the notice does not spell out how the separately payable test gets applied at the pre-submission stage when nobody knows the coding outcome yet.
The benefit category screen is deliberately weak, and the weakness is honest. CMS commits only to checking whether information exists that immediately makes clear the device will not fall under a benefit category. Double negative on purpose. It is a screen for obvious disqualification, not an affirmative determination, and the notice says outright that acceptance into RAPID should not be read as a final benefit category determination. Anyone building software-as-a-medical-device, a digital therapeutic, an AI-enabled monitoring product, or anything else that lives in the statutory dead zone between the Part B benefit categories should treat that sentence as a flashing light. Getting a fast NCD for something with no benefit category is like getting an expedited visa to a country that does not exist.
The IVD carve-out, or how MolDX kept its kingdom
CMS excluded in vitro diagnostics from RAPID entirely. The stated reasoning is that FDA’s statutory definition of device sweeps in IVDs including diagnostic laboratory tests, that coverage policy for these products is a specialized area, and that CMS has historically delegated the review to particular Medicare Administrative Contractors who should continue to handle it. Translated: the molecular diagnostics coverage program run out of the contractor world is not going to be disturbed, and CMS is not interested in opening a national coverage front on lab tests.
This is a bigger deal than the two paragraphs it gets. A meaningful share of Breakthrough designations have gone to diagnostics, including a lot of the AI-driven and multi-analyte products that generate the most investor enthusiasm. Every one of them is now formally outside the fast lane and back in the world of technical assessment submissions, contractor-level policy, and pricing that runs through the clinical laboratory fee schedule with its own gapfill and crosswalk drama. The notice leaves a door cracked, saying that in rare cases where a manufacturer and CMS agree an NCD is appropriate for an IVD, a conventional NCD request can still be filed. Nobody should build a plan around that sentence.
There is a defensible policy argument here. National coverage determinations are blunt instruments for diagnostics, where clinical utility varies enormously by indication, by line of therapy, and by what the clinician does with the result. A contractor-level program can move faster and iterate more than the national process, and it does. There is also a less flattering reading, which is that a national fast track for diagnostics would have created immediate pressure on the pricing side, and pricing for lab tests is a fight CMS has been losing in a slow, grinding way for years. Either way, the diagnostics community should read the exclusion as a signal about where the agency intends to spend its scarce coverage staff, and plan accordingly.
Coverage is not payment, and payment is where the year goes
Here is the part that will disappoint anyone reading the fact sheet without a reimbursement person in the room. An NCD says Medicare covers the thing. It does not say what Medicare pays, or under what code, or in which setting, or starting when. Those are separate processes on separate calendars, and none of them accelerate just because a coverage decision landed early.
A device that needs a new HCPCS Level II code enters an application cycle with published deadlines and preliminary and final decision meetings. A device seeking a new technology add-on payment in the inpatient setting applies against the IPPS rulemaking calendar, which means an application filed in the fall gets proposed in the spring rule and effective the following October first, assuming it clears the substantial clinical improvement test, which has its own evidentiary standard that overlaps with but is not identical to the coverage standard. A device seeking transitional pass-through status in the outpatient setting applies on a quarterly cycle and, if granted, gets a limited window of separate payment before the cost is folded back into the APC. Physician work associated with a new procedure needs a CPT code, which runs through an editorial panel with its own meeting calendar, and then valuation, which runs through a different committee and lands in the physician fee schedule rule.
Stack it up and a device can hold a final NCD in month three post-authorization and still be waiting on a workable payment rate in month fifteen. The notice does not address this, which is a real omission given that TCET at least gestured at coordinating benefit category, coding, and payment reviews as part of its design. RAPID says nothing comparable. If the agency wants the pathway to change commercial outcomes rather than just press releases, the coding and payment side needs a companion process, and the comment period is the moment to say so in writing with specific deadline alignments proposed rather than a general plea for coordination.
The same-day NCD is hostage to FDA’s publishing calendar
The centerpiece commitment, proposed NCD posted the same day as market authorization, has a dependency the notice states plainly and then moves past. Timing is contingent on the relevant FDA Decision Summary for a De Novo or the Summary of Safety and Effectiveness Data for a PMA being publicly available on the day of authorization. CMS will link to it from the tracking sheet. This matters because CMS is required to build an NCD on publicly available information, and the confidential IDE final report that FDA shares with CMS cannot be the public evidentiary basis. The Decision Summary or SSED has to carry the weight.
Anyone who has waited for an SSED knows these documents have not historically appeared the same day as the approval letter. They appear when they appear, sometimes weeks later, occasionally longer, and their content reflects an internal negotiation about what gets disclosed. RAPID therefore requires a change in FDA publication practice, not just a change in CMS analytical sequencing, and the notice does not describe how that change gets operationalized or what happens when the summary slips. A one-week slip turns a same-day proposed NCD into a one-week-late proposed NCD, which is fine. A two-month slip while a redaction dispute gets resolved turns the whole timeline into a normal NCD with better branding.
There is a second-order effect worth watching. The SSED becomes a load-bearing coverage document rather than a transparency artifact. Manufacturers will start negotiating its contents with an eye toward what CMS needs to see, particularly around subgroup results in the Medicare-eligible population. Regulatory affairs teams that have historically treated the SSED as an afterthought at the end of an exhausting review will need to treat it as the first page of the coverage file. That is a genuine workflow change and a genuine consulting opportunity for whoever gets there first.
CED is where the Class III devices go to sit down
The notice is refreshingly honest that a chunk of RAPID NCDs will land under coverage with evidence development rather than full coverage. The logic it offers is risk-stratified: lower-risk devices are more likely to have generated enough evidence by market authorization to satisfy the reasonable and necessary standard, while higher-risk devices are more likely to have residual gaps requiring more evidence under the separate CED authority. Since Class III PMA devices are by definition the higher-risk cohort, the implication is that the 90-day Class III timeline frequently delivers a CED decision rather than open coverage.
CED is not nothing. It is coverage. But operationally it is a different animal. Coverage of related services begins once a CED study is approved, which means the final NCD is not the last gate. There is a protocol, there is CMS review of that protocol, and there is review of the CED framework by the health services research agency that has statutory responsibility for defining the research standards. Approved studies then appear on a CMS web page, and providers who want to furnish the device have to be participating in one. Anyone who lived through the transcatheter aortic valve registry buildout knows what that means for diffusion: coverage exists, but it exists at participating centers, with data submission obligations, with credentialing and volume expectations layered on top by the specialty societies, and with a long tail before the technology reaches a community hospital.
The one meaningful improvement RAPID offers here is the commitment to engage before market authorization so that CED requirements align with any FDA-required post-approval study. Running one study that satisfies two agencies instead of two studies that satisfy one each is real money and real time. That is a genuine efficiency, and if it holds, it is arguably a larger contribution than the same-day NCD headline. The notice also emphasizes that CED is meant to be time-limited, that a cycle completes when CMS reconsiders and drops the study participation requirement, and that any member of the public can request a reopening. Whether that discipline materializes is an empirical question with a discouraging track record. Several CED policies have outlived the technologies they were built to study.
Trial economics: what it costs to design for two agencies
The price of admission to RAPID is designing an IDE study that enrolls Medicare beneficiaries and measures clinical outcomes, defined the old-fashioned way as direct measures of how a patient feels, functions, or survives. Surrogate endpoints, biomarker shifts, and imaging changes are not what CMS means. This is a substantive constraint with a substantive cost.
Enrolling older patients with multiple chronic conditions raises screening burden, raises dropout, raises adverse event rates that have nothing to do with the device, and can dilute a treatment effect that looked clean in a healthier cohort. Powering for a credible read in the 65-plus stratum, rather than just permitting those patients to enroll, means a larger trial, which means more sites, longer enrollment, and more money. Functional and survival endpoints usually mean longer follow-up than the mechanistic endpoints a sponsor might otherwise pick. For an IDE pivotal that already runs somewhere in the low tens of millions for a Class III implantable, the Medicare-facing design changes plausibly add twenty to forty percent to cost and six to eighteen months to timeline, before anyone accounts for the risk that the harder endpoint simply fails.
That last risk is the one boards should be modeling explicitly. There is a real scenario in which the study design that maximizes coverage probability reduces authorization probability, because a functional endpoint in a sicker population is harder to hit than the endpoint the sponsor would have chosen alone. The notice’s mechanism for handling this, FDA determines which clinical outcomes are appropriate and CMS confirms whether evidence on those outcomes in the Medicare population would demonstrate improvement, is a reasonable attempt to keep the two agencies from pulling in opposite directions. It is still two agencies with veto power over a protocol, and the manufacturer is the one financing the compromise.
The calculus is straightforward for a company whose Medicare mix is 70 percent, which describes most of structural heart, electrophysiology, spine, wound care, and a lot of DME. It is much less obvious for a company whose Medicare mix is 25 percent and whose commercial payers have historically moved on their own timeline. For that second group, RAPID asks for a large investment in a trial redesign to accelerate a coverage decision for a minority of revenue.
The free option, and the adverse selection it invites
Buried in the general principles is a provision that changes the strategic character of the whole pathway. A manufacturer may withdraw from RAPID at any point up until CMS issues a proposed NCD, for essentially any reason, with incomplete or insufficient data given as an example, and with the alternative of pursuing local coverage explicitly named as a legitimate motive.
Think about what that creates. A sponsor enters the pathway, gets four years of privileged access to CMS thinking, gets written feedback on evidence gaps, gets its protocol shaped by both agencies, runs the study, and then looks at the unblinded results. If they are strong, it files the NCD request letter and takes the same-day proposed NCD. If they are ambiguous, it withdraws and quietly pursues an LCD or claim-by-claim adjudication, where the evidence bar is applied by a contractor rather than by the national coverage group, where there is no 30-day national comment period for competitors and specialty societies to file objections, and where there is no permanent national document memorializing the fact that CMS looked at the data and was unimpressed.
That asymmetry is rational for the sponsor and awkward for CMS. A negative national coverage determination is a company-ending event in a way that a quiet retreat to contractor-level coverage is not. So the population of devices that actually reach the RAPID NCD stage will be selected for strength, which is fine for beneficiaries and fine for the agency’s success metrics, but it means the pathway’s eventual batting average will overstate its effect. The devices that would have been genuinely uncertain calls will not be in the sample. Anyone evaluating RAPID’s performance in 2032 should ask how many entrants withdrew and where they went, not just how many NCDs got issued in 60 days.
There is a countervailing lever. CMS and FDA reserve the right to eject a manufacturer that fails to provide requested information or is found falsifying or omitting material facts. That handles bad faith. It does not handle rational withdrawal, and it is not meant to.
Medicare Advantage, commercial followers, and the real prize
Roughly 51 percent of the beneficiary population sits in Original Medicare as of 2025, about 34 million people out of nearly 70 million. The other half is in Medicare Advantage, and MA plans are obligated to furnish the Part A and Part B benefits, which means an NCD binds them too. A same-day proposed NCD followed by a 60-day final therefore reaches the entire Medicare population, not just the fee-for-service half, which is a substantially better outcome than a favorable LCD covering one contractor’s jurisdiction.
The nuance is utilization management. Where national coverage criteria are fully established, MA plans have limited room to layer their own internal criteria on top, and recent policy has tightened that further. Where the NCD comes out under CED, the picture gets murkier, because participation in an approved study becomes a condition of coverage and MA network configurations may or may not include participating centers. That is an unresolved operational question the notice does not touch, and it is a legitimate comment topic for anyone with an MA-heavy account base.
The larger prize sits outside Medicare entirely. Commercial medical policy departments do not follow NCDs automatically, but they read them, and a favorable national determination with a public evidence summary is the single most useful artifact a device company can put in front of a commercial medical director. The historical pattern is a lag of somewhere between six and twenty-four months from a positive NCD to broad commercial policy alignment, faster where specialty society guidelines move in parallel. Pulling the NCD forward by nine months pulls the commercial cascade forward by roughly the same amount, which compounds. For a venture-backed device company burning eight figures a year while waiting for the reimbursement flywheel to catch, that is the difference between one more round and an acqui-hire.
Timeline math: when the first RAPID NCD actually shows up
Do the arithmetic on the pre-submission-only entry rule. A company that decides today to enter RAPID needs Breakthrough designation in hand, which takes months if it does not have one, and TAP enrollment if it is on the Class II track. Then comes the interest email, eligibility screening, the preliminary benefit category assessment, the kickoff meeting, the written feedback request, and the protocol revisions that follow. Call that six to twelve months of pre-submission work, which is not pessimistic for a process involving two agencies and a document that both must effectively agree on.
Then the formal IDE goes to FDA, which reviews on its normal clock and issues study design considerations. Those get addressed, FDA blesses a revised protocol, and only then does CMS run its own IDE review. Call that another six to nine months in the good case. Now the pivotal starts. A Class III implantable trial with functional or survival endpoints and a Medicare-representative population is two to four years from first enrollment to database lock, and that is before follow-up requirements that often extend to twelve or twenty-four months post-procedure. Then the PMA gets filed and reviewed, historically the better part of a year.
Add it up and the earliest plausible completion for a device entering the pathway from a standing start in late 2026 is somewhere in 2031 or 2032. Even a company that already has designation, already has TAP, and already has a protocol nearly ready cannot realistically beat 2030. Which means the administration announcing this pathway will be out of office before it produces its first same-day NCD, and the fact sheet’s promise of accelerated access describes something that happens after the next two presidential elections.
This is precisely why the comment solicitation on a temporary on-ramp for devices already under an active IDE is the whole ballgame. If CMS builds that on-ramp, devices currently mid-study could amend protocols or demonstrate that existing endpoints already satisfy the requirement, and the pathway could produce output in 2028 or 2029 instead. If CMS does not, RAPID is a policy commitment to a successor administration that has no obligation to honor it, and the odds of it surviving intact through a transition are not good given that its two predecessors did not.
What belongs in a comment letter before the window closes
Comments are due 60 days after the August 11 publication, filed under file code CMS-3487-NC. Four topics deserve the ink.
The on-ramp question deserves the most, and the answer should be yes with specifics rather than yes in principle. A useful letter proposes a defined window, describes the criteria under which an in-flight IDE could be deemed adequate without amendment, and addresses what happens when a partial amendment is needed mid-enrollment, including whether previously enrolled subjects count. Vague enthusiasm will not move a drafting team; a proposed operational test might.
The coding and payment gap deserves the second most. A letter that documents actual elapsed time from NCD to workable payment rate for two or three recent technologies, and proposes calendar alignment between RAPID acceptance and the relevant coding application deadlines, is worth more than a hundred letters asking CMS to consider coordination. The point is that a same-day coverage decision paired with a fifteen-month wait for a rate is not access.
The separately payable criterion deserves clarification, because applying a payment-status test at the pre-submission stage, years before any coding determination, is either meaningless or arbitrary depending on how it gets implemented. Manufacturers should ask CMS to state what evidence establishes separate payability prospectively and whether a good-faith intent to seek pass-through or add-on status suffices.
The IVD exclusion deserves a challenge from the diagnostics community, not to overturn it wholesale but to define the rare case where an NCD is appropriate. As written, that exception is undefined and therefore unusable. A workable version would identify categories, for instance a diagnostic whose result gates access to a therapy already covered under an NCD, where national consistency has obvious value.
Where this leaves builders and capital
For operators, the practical guidance is unglamorous. If a device is Class III, Breakthrough-designated, Medicare-heavy, and has not yet filed an IDE pre-submission, RAPID is worth serious modeling and probably worth entering, because the pre-submission feedback alone is valuable even if the pathway is later abandoned. If a device is mid-study, the correct action this quarter is a comment letter arguing for the on-ramp, followed by a conversation with CMS about conventional options. If the product is an IVD, none of this applies and the contractor route remains the route. If the product is software without a clean benefit category, the coverage timeline was never the binding constraint, and the honest answer is that the statutory gap needs Congress, not a procedural notice.
For investors, the underwriting change is narrower than the headline suggests but not trivial. The classic device valley of death, where a company survives clearance and then dies waiting for coverage, gets shallower for a specific slice of the market: Class II and Class III Breakthrough devices with separate billability and heavy Medicare exposure. For that slice, coverage risk moves earlier in the diligence stack and becomes partly assessable at Series A rather than a black box discovered at Series C. Diligence should now ask whether the pivotal is designed to satisfy CMS as well as FDA, whether Medicare beneficiaries are enrolled in numbers sufficient to read, and whether management has had the pre-submission conversation. A no to all three in a Medicare-dependent category is a finding, not a footnote.
The larger caution is that this is the third federal attempt at the same problem in six years, delivered through the least durable instrument available, dependent on an FDA publishing practice that has not yet changed, silent on the payment machinery that consumes most of the elapsed time, and structurally incapable of producing an output before the end of the decade unless CMS accepts the on-ramp it just asked about. That is a lot of conditional. It is also, on balance, better designed than either predecessor, because it puts the coverage conversation at the moment when a protocol can still be changed cheaply rather than at the moment when the data are already collected and everyone is arguing about what they mean. Aligning expectations before the money is spent is the correct instinct. Whether the federal government can hold that instinct steady for six years across an election is the actual open question, and no procedural notice has ever answered it
.